Page last updated: 2024-10-27

fluorouracil and Benign Supratentorial Neoplasms

fluorouracil has been researched along with Benign Supratentorial Neoplasms in 2 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma."9.11Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. ( Assaker, R; Bataille, B; Bauchet, L; Benoit, JP; Capelle, L; Dorwling-Carter, D; Faisant, N; François, P; Fuentes, S; Guyotat, J; Menei, P; Paquis, P; Parker, F; Sabatier, J, 2005)
"This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)."9.07A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992)
"This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma."5.11Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. ( Assaker, R; Bataille, B; Bauchet, L; Benoit, JP; Capelle, L; Dorwling-Carter, D; Faisant, N; François, P; Fuentes, S; Guyotat, J; Menei, P; Paquis, P; Parker, F; Sabatier, J, 2005)
"This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)."5.07A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Menei, P1
Capelle, L1
Guyotat, J1
Fuentes, S1
Assaker, R1
Bataille, B1
François, P1
Dorwling-Carter, D1
Paquis, P1
Bauchet, L1
Parker, F1
Sabatier, J1
Faisant, N1
Benoit, JP1
Shapiro, WR1
Green, SB1
Burger, PC1
Selker, RG1
VanGilder, JC1
Robertson, JT1
Mealey, J1
Ransohff, J1
Mahaley, MS1

Trials

2 trials available for fluorouracil and Benign Supratentorial Neoplasms

ArticleYear
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial.
    Neurosurgery, 2005, Volume: 56, Issue:2

    Topics: Antimetabolites, Antineoplastic; Biodegradation, Environmental; Combined Modality Therapy; Delayed-A

2005
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
    Journal of neurosurgery, 1992, Volume: 76, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali

1992